6 completed, 6 unknown, 4 withdrawn, 3 terminated. 19 Phase 2, 7 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 6, Unknown 6, Withdrawn 4, Terminated 3 |
| Phase 3 | 7 | Completed 2, Unknown 2, Withdrawn 2, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow SARS-CoV2 Infection: new trials by email Literature Review of SARS-CoV2 Infection trials Research Report on SARS-CoV2 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NAC for Attenuation of COVID-19 Symptomatology N-acetylcysteine, Placebo - Covid19, COVID-19 Pneumonia | Phase 2 | Unknown | Cambridge Health Alliance | 200 | 2024-03-31 | 2023-08-07 |
| Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine PHH-1V81, Comirnaty Omicron XBB1.5 - SARS-CoV2 Infection | Phase 2 / Phase 3 | Completed | Hipra Scientific, S.L.U | 913 | 2023-11-15 | 2026-03-12 |
| International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Fostamatinib, Placebo - COVID-19, SARS-CoV2 Infection | Phase 2 / Phase 3 | Terminated | NEAT ID Foundation | 28 | 2022-10-27 | 2025-05-02 |
| Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea Combination regimen: Fluoxetine, Prednisolone, Ivermectin, Combination regimen: Albendazole, Vitamin C - SARS-CoV2 Infection, COVID-19 | Phase 2 / Phase 3 | Withdrawn | Oriol Mitja | 2022-05-01 | 2023-03-09 | |
| A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine SCTV01C, Comirnaty - COVID-19, SARS-CoV2 Infection | Phase 2 | Withdrawn | Sinocelltech Ltd. | 2022-04-25 | 2024-02-09 | |
| Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 Candesartan Cilexetil, Repagermanium, Candesartan Placebo - COVID-19, SARS-CoV2 Infection | Phase 2 | Terminated | University of Sydney | 49 | 2022-01-07 | 2023-09-15 |
| Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Terminated | Leidos Life Sciences | 4 | 2021-12-29 | 2024-07-09 |
| SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations BMS-986414, BMS-986413 - SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease | Phase 2 | Withdrawn | Imperial College Healthcare NHS Trust | 2021-11-29 | 2023-04-24 | |
| Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Masitinib Mesylate, Placebo - Covid19, SARS-CoV2 Infection | Phase 2 | Unknown | AB Science | 78 | 2021-11-23 | 2023-02-06 |
| Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Basiliximab Injection, Placebo - SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection | Phase 2 | Unknown | Fort Worth Clinical Sciences Working Group | 300 | 2021-10-15 | 2021-08-19 |
| Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines GX-19N, Placebo - SARS-CoV2 Infection | Phase 2 / Phase 3 | Withdrawn | Genexine, Inc. | 2021-10-01 | 2022-04-12 | |
| Efficacy of Ivermectin in COVID-19 Ivermectin, Placebo - Safety, SARS-CoV2 Infection | Phase 1 / Phase 2 | Completed | Bangkok Metropolitan Administration Medical College and Vajira Hospital | 72 | 2021-09-01 | 2021-12-15 |
| Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients Exosome-MSC Intravenous injection, Placebo Intravenous Injection, COVID-19 Standard Treatment - SARS-CoV2 Infection | Phase 2 / Phase 3 | Unknown | Dermama Bioteknologi Laboratorium | 60 | 2021-07-01 | 2022-02-18 |
| COVAXIN in a Pediatric Cohort COVAXIN - SARS-CoV2 Infection | Phase 2 / Phase 3 | Completed | Bharat Biotech International Limited | 525 | 2021-05-26 | 2022-08-18 |
| Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2 Vaxzevria, Comirnaty - SARS-CoV2 Infection | Phase 2 | Unknown | Medical University Innsbruck | 3000 | 2021-05-10 | 2021-09-10 |
| Effect of IMMUNEPOTENT-CRP on Serum Pro-Inflammatory Cytokines in Mild to Moderate COVID-19 IMMUNEPOTENT-CRP (I-CRP), Placebo Comparator - COVID-19, SARS-CoV2 Infection | Phase 1 / Phase 2 | Completed | Universidad Autonoma de Nuevo Leon | 80 | 2021-04-20 | 2024-11-08 |
| Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection Nitazoxanide and Ciclésonide, Telmisartan 20Mg Oral Tablet, Paracetamol - Covid19, Covid19 Drug Treatment | Phase 2 / Phase 3 | Unknown | ANRS, Emerging Infectious Diseases | 600 | 2021-04-12 | 2023-01-31 |
| Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 Rayaldee, Placebo - COVID-19, Coronavirus | Phase 2 | Completed | OPKO Health, Inc. | 171 | 2020-11-02 | 2024-05-28 |
| Sildenafil in COVID-19 Sildenafil, Placebo - Covid19, SARS-COV2 Infection | Phase 1 / Phase 2 | Completed | Universidad Nacional Andres Bello | 40 | 2020-08-19 | 2021-09-29 |
COVID-19 (19) · Cytokine Release Syndrome (3) · Coronavirus Infections (2) · Leukemia (1) · Lymphoma (1) · Neoplasms, Plasma Cell (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Purpura, Thrombotic Thrombocytopenic (1)
Coronaviridae Infections (19) · Infections (19) · Lung Diseases (19) · Nidovirales Infections (19) · Pneumonia (19) · Pneumonia, Viral (19) · RNA Virus Infections (19) · Respiratory Tract Diseases (19) · Respiratory Tract Infections (19) · Virus Diseases (19) · Coronavirus Infections (17) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Inflammation (3) · Shock (3)
BNT162 Vaccine (2) · Ivermectin (2) · Acetaminophen (1) · Acetylcysteine (1) · Ascorbic Acid (1) · BBV152 COVID-19 vaccine (1) · Basiliximab (1) · Calcifediol (1) · Celecoxib (1) · ChAdOx1 nCoV-19 (1) · Famotidine (1) · Fluoxetine (1) · GX-19N vaccine (1) · Prednisolone (1) · SCTV01C vaccine (1)
AB Science (1) · ANRS, Emerging Infectious Diseases (1) · Bangkok Metropolitan Administration Medical College and Vajira Hospital (1) · Bharat Biotech International Limited (1) · Cambridge Health Alliance (1) · Dermama Bioteknologi Laboratorium (1) · Fort Worth Clinical Sciences Working Group (1) · Genexine, Inc. (1) · Hipra Scientific, S.L.U (1) · Imperial College Healthcare NHS Trust (1) · Leidos Life Sciences (1) · Medical University Innsbruck (1) · NEAT ID Foundation (1) · OPKO Health, Inc. (1) · Oriol Mitja (1)
United States (3) · India (2) · South Africa (2) · Spain (2) · Austria (1) · Brazil (1) · Burkina Faso (1) · Chile (1) · France (1) · Germany (1) · Guinea (1) · Indonesia (1) · Italy (1) · Mexico (1) · Russia (1)
Akhtar Ashfaq, MD FACP FASN (1) · Andy Peniket (1) · Anton Pozniak, Prof (1) · Bambang Darwono, Dr.Sp.OT (1) · Brian A Roberts, MS, PMP (1) · Cristina Rodriguez-Padilla, Ph.D. (1) · Dorothee von Laer, MD (1) · Dr Mirza Nizam Baig, MBBS,MD (1) · Dr Padmavathi I V, MBBS,MD (1) · Dr Prashanth Siddiah, MBBS,MD (1) · Dr.Jai Prakash Narayan, MBBS,MD (1) · Dr.Lokesh Kumar Tiwari, MBBS,DNB (1) · Dr.V.N Tripathi, MBBS,MD (1) · Dr.Vasant Khalatkar, MBBS,MD (1) · Felipe Martinez, MD, MSc (1)
PMID 34980198, PMID 35617826, PMID 35717995, PMID 36028897, PMID 36048877, PMID 36574985, PMID 39438096